CoChat

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

Open access
Sarris, Jerome, Sinclair, Justin, Karamacoska, Diana, Davidson, Maggie, Firth, Joseph · 2020 · BMC Psychiatry

Abstract

Background: Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods: The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding whole plant formulations and plant-derived cannabinoid isolates in mood, anxiety, sleep, psychotic disorders and attention deficit/hyperactivity disorder (ADHD) is discussed; while also detailing clinical prescription considerations (including pharmacogenomics), occupational and public health elements, and future research recommendations. The systematic review of the literature was conducted during 2019, assessing the data from all case studies and clinical trials involving medicinal cannabis or plant-derived isolates for all major psychiatric disorders (neurological conditions and pain were omitted). Results: The present evidence in the emerging field of cannabinoid therapeutics in psychiatry is nascent, and thereby it is currently premature to recommend cannabinoid-based interventions. Isolated positive studies have, however, revealed tentative support for cannabinoids (namely cannabidiol; CBD) for reducing social anxiety; with mixed (mainly positive) evidence for adjunctive use in schizophrenia. Case studies suggest that medicinal cannabis may be beneficial for improving sleep and post-traumatic stress disorder, however evidence is currently weak. Preliminary research findings indicate no benefit for depression from high delta-9 tetrahydrocannabinol (THC) therapeutics, or for CBD in mania. One isolated study indicates some potential efficacy for an oral cannabinoid/terpene combination in ADHD. Clinical prescriptive consideration involves caution in the use of high-THC formulations (avoidance in youth, and in people with anxiety or psychotic disorders), gradual titration, regular assessment, and caution in cardiovascular and respiratory disorders, pregnancy and breast-feeding. Conclusions: There is currently encouraging, albeit embryonic, evidence for medicinal cannabis in the treatment of a range of psychiatric disorders. Supportive findings are emerging for some key isolates, however, clinicians need to be mindful of a range of prescriptive and occupational safety considerations, especially if initiating higher dose THC formulas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-019-2409-8

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 114 references

Research works printed but not linked: 4

  1. Grierson G. The hemp plant in Sanskrit and hindi literature. Indian Antiqu. 1894;September:260–2.
  2. HelloMD. Medical marijuana: patient survey results. 2016.
  3. WorkCover NSW. Alcohol and other drugs in the workplace: guide to developing a workplace alcohol and other drugs policy. Perth: WorkCover NSW; 2006.
  4. CCOHS. Workplace strategies: risk of impairment from cannabis. In: Safety CCfOHa. Ontario: Candian Centre for Occupational Health and Safety; 2018.

Cited by

See all 261

Metadata

Authors
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J.
Affiliations
  • The University of Melbourne (AU)
  • Western Sydney University (AU)
  • University of Manchester (GB)
Corresponding author
Sarris, Jerome
Venue
BMC Psychiatry
Published
2020-01-16
Volume
20
Issue
1
Pages
24-24
ISSN
1471-244X (ISSN-L)
OpenAlex
W3004703759
Cited by
253
References
114
Citations by year
2026: 21 · 2025: 33 · 2024: 50 · 2023: 46 · 2022: 41 · 2021: 44 · 2020: 18
FWCI
4.89
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
Funders
National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
medical cannabis, mental illness, cannabidiol, tetrahydrocannabinol, social anxiety, schizophrenia, post-traumatic stress disorder, depression, mania, attention deficit hyperactivity disorder, sleep, pharmacogenomics, terpenes, cannabis regulation
MeSH terms
Adolescent, Anxiety, Cannabidiol, Cannabinoids, Cannabis, Child, Humans, Medical Marijuana

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. https://app.cochat.ai/papers/10.1186/s12888-019-2409-8
The paper
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020). Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. https://doi.org/10.1186/s12888-019-2409-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.